Plain-English translation of NCT06818682 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining radiation therapy with a shorter course of hormone therapy—9 months instead of the standard 2 years—plus a newer hormone medication like abiraterone or enzalutamide can work just as well for men with high-risk prostate cancer. The goal is to control the cancer while reducing the side effects that come from taking hormone therapy for a long time. The study will compare this new approach to the standard treatment that most men receive today.
Long-term hormone therapy can cause significant side effects like fatigue, weight gain, and weakened bones. Researchers believe that by shortening the duration and adding newer, more powerful hormone medications, they may be able to maintain the same cancer control while reducing these long-term side effects and improving quality of life.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: either radiation to your prostate and pelvic lymph nodes combined with 9 months of standard hormone therapy plus 6 months of a newer hormone medication, or radiation combined with the standard 2 years of hormone therapy alone. You would take the hormone medications by mouth as prescribed and receive radiation therapy over several weeks. Throughout the study, you would have regular clinic visits to monitor how you are doing, check your PSA levels, and assess any side effects. The study will track your cancer control, survival, and quality of life over time.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
India